Lopinavir as a Potential Inhibitor for SARS-CoV-2 Target Protein: A Molecular Docking Study
8 Pages Posted: 18 May 2020
Date Written: May 9, 2020
COVID-19 has been the reason for the pandemic, which is induced by the SARS-CoV-2. Potential drugs are being used for its cure, but there's no specific drug for it. To get a specific drug, many drug designing strategies are being used in which molecular docking plays a vital role in computer-assisted drug designing. In this research, we've tested the molecular docking of Lopinavir (LV) on the Receptor Binding Spike proteins of SARS-CoV-2. We’ve generated the ADMET properties consistent with predicted ADMET parameters supported Lipinski’s rule with the aid of the Datawarrior software version 5.2.1.
Funding:The authors are thankful to Abeda Inamdar College, Pune-411001 for their support. We are also thankful to Innovative informatics Technologies, Miyapur Hyderabad, India for their help in the analysis of docking studies and physical properties.
Declaration of Interest: The authors declare that they have no conflict of interest.
Ethical Approval: This chapter does not contain any studies with human participants or animals performed by any of the authors.
Keywords: SARS-CoV-2, COVID-19, Spike protein, Molecular Docking, Lopinavir
Suggested Citation: Suggested Citation